

Ying-Hao Shen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/706241/publications.pdf>

Version: 2024-02-01

31
papers

735
citations

623734

14
h-index

580821

25
g-index

36
all docs

36
docs citations

36
times ranked

1149
citing authors

#	ARTICLE	IF	CITATIONS
1	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. <i>Liver Cancer</i> , 2021, 10, 320-329.	7.7	108
2	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 846-861.	1.8	84
3	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , 2019, 9, 4678-4687.	10.0	61
4	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	6.8	43
5	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. <i>BMC Cancer</i> , 2017, 17, 58.	2.6	42
6	NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. <i>Journal of Hematology and Oncology</i> , 2018, 11, 28.	17.0	41
7	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2016, 49, 2367-2376.	3.3	39
8	Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. <i>BMC Cancer</i> , 2015, 15, 831.	2.6	34
9	Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , 2017, 8, 3205.	6.3	34
10	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 169-178.	1.5	32
11	Focal nodular hyperplasia of the liver in 86 patients. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2007, 6, 52-7.	1.3	31
12	Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 204-204.	1.7	25
13	Generation and characterization of a tetraspanin CD151/integrin $\alpha 6 \beta 1$ -binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. <i>Oncotarget</i> , 2016, 7, 6314-6322.	1.8	20
14	Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk. <i>Tumor Biology</i> , 2014, 35, 4007-4015.	1.8	19
15	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 705378.	4.8	17
16	CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. <i>Carcinogenesis</i> , 2021, 42, 1293-1303.	2.8	16
17	Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	1.9	12
18	Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16690-e16690.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. <i>American Journal of Cancer Research</i> , 2018, 8, 1040-1049.	1.4	11
20	Simulation of portal/hepatic vein associated remnant liver ischemia/congestion by three-dimensional visualization technology based on preoperative CT scan. <i>Annals of Translational Medicine</i> , 2021, 9, 756-756.	1.7	8
21	Dexamethasone for postoperative hyperbilirubinemia in patients after liver resection: An open-label, randomized controlled trial. <i>Surgery</i> , 2019, 165, 534-540.	1.9	7
22	A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. <i>Surgery</i> , 2020, 167, 926-932.	1.9	7
23	Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 13-20.	1.3	7
24	Development and Validation of a Nomogram Based on Perioperative Factors to Predict Post-hepatectomy Liver Failure. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	7
25	Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16610-e16610.	1.6	7
26	Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 3567-3578.	0.0	5
27	Factors influencing adjuvant treatment decision making among Chinese patients with hepatocellular carcinoma (HCC): Results of a patient survey.. <i>Journal of Clinical Oncology</i> , 2021, 39, 346-346.	1.6	2
28	Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 304-304.	1.6	2
29	Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16144-e16144.	1.6	1
30	Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. <i>Surgical Innovation</i> , 2022, 29, 145-153.	0.9	0
31	Future liver volume combined with platelet count predicts liver failure after major hepatectomy. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, , .	1.8	0